Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are reported to reduce body fat in patients with type 2 diabetes mellitus (T2DM), and SGLT2i-induced weight reduction may help improve comorbid nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the potential benefit of SGLT2...

Descripción completa

Detalles Bibliográficos
Autores principales: Euh, Won, Lim, Soo, Kim, Jin-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222919/
https://www.ncbi.nlm.nih.gov/pubmed/34177796
http://dx.doi.org/10.3389/fendo.2021.613389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222919/
https://www.ncbi.nlm.nih.gov/pubmed/34177796
http://dx.doi.org/10.3389/fendo.2021.613389

Ejemplares similares